Allogene Therapeutics, Inc. (ALLO)

Allogene Therapeutics, Inc. is a pioneering biotechnology company dedicated to developing and commercializing innovative allogeneic CAR-T cell therapies for cancer treatment. Founded in 2017 by Arie Belldegrun and David Chang, the company is at the forefront of developing off-the-shelf CAR-T therapies designed to be accessible, effective, and widely available to patients in need. As of now, David Chang serves as the President and CEO of the company. Allogene Therapeutics focuses on transforming the landscape of cancer treatment by overcoming the limitations of autologous therapies, aiming for more efficient, scalable, and cost-effective solutions. The company is based in South San Francisco, California, and continues to make strides in clinical research, targeting various cancers to improve patient outcomes. While specifics like revenue figures and current financial performance can vary, Allogene is publicly traded on the NASDAQ under the ticker “ALLO.” The company is well-regarded in the biotech sector for its innovative approach and commitment to advancing cancer immunotherapy.